Does rapamycin extend healthspan and lifespan in humans?
Claim attributed to Longevity physicians and biohackers (e.g. Peter Attia; the late Mikhail Blagosklonny's following; off-label "rapa" users) , Rapamycin (sirolimus) is an FDA-approved immunosuppressant, for organ-transplant rejection, certain cancers, and drug-eluting stents, used entirely off-label for longevity. The lifespan claim rests on a genuinely strong animal literature (the NIA Interventions Testing Program mouse studies, via mTOR inhibition), which proponents extrapolate to people. No regulator anywhere has approved rapamycin for aging, healthspan, or longevity.
In mice, rapamycin is the most reproducible life-extending drug we have. In humans, no trial has ever measured lifespan or mortality, and the largest healthspan trial to date missed its primary endpoint. The mouse science is real; the human longevity claim is untested, not demonstrated.
Reliably extends life in mice; in humans, no one has measured whether it extends life at all, and the biggest healthspan trial, run by a company that sells it, missed its main target.
What it’s supposed to target
- mTOR (mTORC1)
- Autophagy
- Cellular growth signaling
- Caloric-restriction mimicry
Rapamycin (sirolimus) inhibits mTOR, specifically the mTORC1 complex, the cell's central nutrient sensor. mTORC1 normally reads abundance (amino acids, growth factors, energy) and pushes cells to grow and divide, so turning it down imitates part of what caloric restriction does, the most reproducible way to extend lifespan in lab animals. The proposed chain: less mTOR signaling → more autophagy (cells recycle their own damaged parts) and less of the growth and inflammatory drive thought to speed aging.
This is the best-pedigreed mechanism in longevity science: mTOR inhibition extends lifespan in yeast, worms, flies and, crucially, mice, where the NIA Interventions Testing Program confirmed it repeatedly, even when started late in life. That animal record is why rapamycin is taken seriously where most longevity ideas are not. The catch is that mice are not people: the dose and schedule that might extend human healthspan are unknown, and mTOR inhibition is double-edged (immune suppression, metabolic effects), so a strong mechanism is not yet a proven human anti-aging drug.
Mechanism is theory, not proof. A plausible pathway explains why something might work, not whether it does. The verdict rests on the evidence below, not the elegance of the theory.
What would have to be true
mTOR inhibition slows aging mechanisms such as autophagy and stress resistance, conserved across species, HOLDS, one of the best-validated geroscience mechanisms.
This translates into longer lifespan in mammals, HOLDS in mice, via the replicated, dose- and sex-dependent NIA ITP studies.
It translates into longer healthspan in humans at tolerable, intermittent doses, UNRESOLVED; human trials are short and surrogate-based, and the largest one missed its primary endpoint.
It translates into longer human lifespan without offsetting harm over decades, UNTESTED; no mortality trial exists and long-term safety in healthy adults is unknown.
What the evidence actually shows
The animal evidence is genuinely strong, and government-funded
The case for rapamycin begins with the best mouse data in the field. The US National Institute on Aging's Interventions Testing Program tests drugs in genetically heterogeneous mice across three independent labs, a design built to weed out single-site flukes. In *Nature* (2009), rapamycin started late in life (600 days, roughly human age 60) still extended median lifespan +13% in females and +9% in males. A higher-dose follow-up in *Aging Cell* (2014) pushed gains to +23% (males) and +26% (females), dose- and sex-dependent and metabolically distinct from caloric restriction. A 2020 ITP paper confirmed the effect again across dosing schedules. Crucially, this work was funded by the NIA and the Department of Veterans Affairs, no industry sponsor, no commercial conflict. This is the rare longevity claim where the most favourable evidence is also the most independent.
In humans, the lifespan endpoint has never been measured, and the best trial missed
No randomized trial has ever tested whether rapamycin reduces mortality or extends survival in people; every human study uses short-term, surrogate, or self-reported endpoints. The largest healthspan trial, PEARL (n=114 completed, 48 weeks, low-dose intermittent), missed its primary endpoint, change in visceral fat by DXA (p=0.942), with only scattered sex-specific and self-reported secondary signals. PEARL was run by employees and shareholders of AgelessRx, a company that sells off-label rapamycin, and crowdfunded via Lifespan.io. A 2024 *Lancet Healthy Longevity* systematic review (19 studies, 18,400 screened) found rapalogs improved some immune, cardiovascular and skin parameters but not endocrine, muscular or neurological ones, and assessed no mortality outcome. And one human pivotal trial actually failed: resTORbio's Phase 3 of the rapalog RTB101 did not reduce respiratory infections in adults 65+ (odds ratio 1.07, p=0.65), and the program was halted, an earlier positive immune surrogate that did not survive scale-up.
Studies, graded, and who paid
Replicated across three independent NIA-funded sites, even when started late in life; among the most robust findings in geroscience.
No randomized trial has ever measured human mortality or survival; the claim is pure animal-to-human extrapolation.
Mixed: some immune/cardiovascular/skin signals, but the largest trial missed its primary endpoint and a Phase 3 rapalog trial failed outright.
| # | Study | Type | Size | Funding / COI | Key limitations |
|---|---|---|---|---|---|
| 1900 | Harrison 2009, Nature (NIA ITP) | Randomized controlled mouse lifespan study, 3 sites | ~1,901 UM-HET3 mice | Independent NIA grants + US Dept of Veterans Affairs; no industry. | Mouse data only; says nothing directly about humans. |
| 0 | Miller 2014, Aging Cell (NIA ITP) | Randomized controlled mouse lifespan study | UM-HET3 mice, multiple dose arms | Independent NIA Interventions Testing Program; no industry sponsor. | Mouse data only; effect dose- and sex-dependent; high exposure unlike tolerable human dosing. |
| 218 | Mannick 2014, Sci Transl Med | Randomized placebo-controlled human trial (surrogate immune endpoint) | Elderly adults, flu-vaccine response endpoint | Industry-funded Novartis-sponsored; authors Novartis-affiliated. Favourable surrogate, flagged. | Surrogate endpoint (vaccine response) only; no healthspan or lifespan outcome. |
| 0 | resTORbio PROTECTOR 1, Phase 3 (2019) | Phase 3 randomized human trial (clinical infection endpoint), failed | n=1,024 adults aged 65+ | Industry-funded Funded by resTORbio (Novartis-derived). Negative pivotal result; program halted. | Endpoint was respiratory infection, not aging; OR 1.07, p=0.65. |
| 114 | PEARL trial, Aging (Albany NY) 2025 | Randomized double-blind placebo-controlled human trial (surrogate/self-report) | 125 randomized, 114 completed; aged 50–85 | Industry-funded Run by AgelessRx employees/shareholders (sells rapamycin); crowdfunded. Conflict flagged. | Primary endpoint (visceral fat) missed, p=0.942; positive findings are secondary/self-reported; no mortality endpoint. |
Unproven ≠ disproven
The verdict is Unproven, not Unsupported: the human longevity claim has never been tested with a mortality endpoint, so it cannot be said to have failed, only to be undemonstrated. The one rapalog program taken to a hard human endpoint (RTB101, respiratory infection) did fail, but that targeted infection, not aging.
Where claim and evidence diverge
The whole claim hinges on the leap from mouse to human, and that link has no direct human evidence: not one trial measures whether people who take rapamycin live longer or stay healthier for longer.
The money trail
The strongest pro-rapamycin evidence (mouse lifespan) is government-funded and conflict-free, a point in its favour. But the most-promoted human trial, PEARL, was designed and run by AgelessRx, a telehealth company that sells off-label rapamycin, and crowdfunded rather than independently granted; its favourable headlines rest on secondary, self-reported endpoints after the primary endpoint missed.
The honest read
Take the mouse data seriously and the human marketing skeptically. Rapamycin is the most credible drug in geroscience on mechanism, but no human has been shown to live longer or healthier on it, and people are dosing themselves off-label, unmonitored, on the strength of mouse numbers.
What would change this verdict
A randomized controlled trial in humans with a hard endpoint, mortality, incident age-related disease, or validated functional healthspan, showing benefit that survives independent replication.
A long-term safety dataset in healthy aging adults showing intermittent dosing does not raise infection or cardiometabolic harm enough to offset any benefit.
Sources
- Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395.
- Miller RA, Harrison DE, Astle CM, et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2014;13(3):468-477.
- Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179.
- resTORbio, Inc. Phase 3 PROTECTOR 1 trial of RTB101 in clinically symptomatic respiratory illness did not meet the primary endpoint (press release, 15 Nov 2019).
- Moel M, Zalzala S, Isman A, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY). 2025.
- Lee DJW, et al. Targeting ageing with rapamycin and its derivatives in humans: a systematic review. Lancet Healthy Longevity. 2024;5(2):e152-e162.
- Juricic Dzankic P, Partridge L. Clinical trials of mTOR inhibitors to boost immunity to viral infection in older adults (commentary). Lancet Healthy Longevity, 2021.
- Strong R, Miller RA, Harrison DE, et al. Rapamycin-mediated mouse lifespan extension: late-life dosage regimes with sex-specific effects. Aging Cell. 2020;19(11):e13269.
People also ask
- Does rapamycin extend lifespan in mice?
- Yes, robustly. It is replicated across three independent NIA-funded sites, even when started late in life, making it among the most reproducible life-extending drugs in geroscience. The mouse science is genuinely strong.
- Does rapamycin extend lifespan in humans?
- This is untested. No randomized trial has ever measured human mortality or survival; the claim is pure animal-to-human extrapolation. Not one trial measures whether people who take rapamycin live longer.
- Does the PEARL trial prove rapamycin improves healthspan?
- Not convincingly. PEARL was designed and run by a telehealth company that sells off-label rapamycin and was crowdfunded; its favourable headlines rest on secondary, self-reported endpoints after the primary endpoint missed.
- Is it safe to take rapamycin off-label for longevity?
- The human safety picture is incomplete. People are dosing themselves off-label and unmonitored on the strength of mouse data. A long-term safety dataset in healthy aging adults, checking infection and cardiometabolic risk, is exactly what is still missing.
Compare head to head: Rapamycin vs metformin: which has the stronger longevity case?
Caveat is journalism, not medical advice. We check public claims against published evidence; we don’t diagnose, treat, or tell you what to take.